Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Found vs Henry Meds

Two GLP-1 desks, one scoreboard. We put Found and Henry Meds head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 33 · Grade B−

Found

Visit Found Full brief →
vs
Higher Brief ScoreNo. 31 · Grade B

Henry Meds

Visit Henry Meds Full brief →

The verdict

Henry Meds takes this head-to-head.

Henry Meds scores 84 to 81 on our six-factor Brief Score — A flat-fee compounded pioneer — simple model, but its price has drifted to the higher end of our ranking.

That doesn't make Found a bad call — it's best for readers who want insurance run against their clinical visits and a clinician free to move them between compounded, brand and oral routes. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
85
Supply Reliability
88
84
Transparency
62
85
Access Breadth
92
82
Clinical Oversight
90
84
Track Record
86
85
FoundBrief Score 81 · 84Henry Meds

Price, coverage & the tracker

FoundHenry Meds
Brief Score81/100 (B−)84/100 (B)
Semaglutide$289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); the advertised $99 is the in-network INSURANCE rate and still sits before a ~$30 per-visit copay$249/mo
Tirzepatide$289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); one program price covers both molecules$349/mo
CoverageAll 50 statesMulti-state
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableRisingprice rising

Found: Headline unchanged, but our $129 line was wrong: the published floor is $99 and it requires a 3-, 6- or 12-month plan.

Henry Meds: Flat-fee pioneer, but its line has drifted to the higher end of the tracker.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.